Safety Profile of VMAT2 Inhibitors and Impact on Treatment Selection

Panelists discuss how VMAT2 inhibitors' most commonly reported adverse effects include somnolence, fatigue, and mild parkinsonism symptoms, which can typically be managed through dose adjustments and careful titration strategies, while noting these side effects are generally less severe than those of older treatments and rarely lead to discontinuation when patients are properly monitored and educated about expectations.